Pharvaris (NASDAQ:PHVS – Get Free Report)‘s stock had its “overweight” rating reiterated by investment analysts at Morgan Stanley in a research report issued to clients and investors on Monday, Benzinga reports. They presently have a $34.00 price target on the stock. Morgan Stanley’s price objective indicates a potential upside of 64.65% from the stock’s previous […]

Related Keywords

, Blackstone Inc , Morgan Stanley , Walleye Capital , Bio Partners , Pharvaris Company Profile , Nasdaq , Get Free Report , Bay Capital Management , Commodore Capital , Pharvaris Daily , Pharvaris , Nasdaq Phvs , Phvs , Medical , Reiterated Rating ,